Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: review decision - January 2015 information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - GE decision paper - January 2015 (PDF 74 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: review proposal November 2014 information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - provisional matrix of stakeholders (PDF 99 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix B - proposal paper presented to the Institutes Guidance Executive (PDF 248 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment - guidance development (PDF 74 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: final appraisal determination information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: final appraisal determination document (PDF 299 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 190 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: consultee and commentator comments on the ACD

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche (PDF 499 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Nursing (PDF 51 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Pathologists (PDF 3.5 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO) (PDF 253 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Department of Health (PDF 45 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: NHS Birmingham East and North (PDF 63 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Commissioning Support Appraisal Service (PDF 321 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: addendum by Liverpool Research Implementation Group (LRiG) (PDF 473 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: comments on the ACD received from the public through the NICE website (PDF 79 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation 2

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation document 2 information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: consultee and commentator comments on the ACD

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche Products (PDF 1.58 MB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: British Association of Dermatologists (PDF 35 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Nursing (PDF 57 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO) (PDF 344 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Department of Health (PDF 5.8 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Commissioning Support Appraisals Service (PDF 312 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Lorigan (PDF 36 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: comments on the ACD received from the public through the NICE website (PDF 162 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation document information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: evaluation report

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: pre-meeting briefing (PDF 466 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report (PDF 1.31 MB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - superseded pages information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - superseded pages (PDF 188 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - addendum information

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - addendum (PDF 417 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - factual accuracy check (PDF 335 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: manufacturer submission

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche Products (PDF 4.51 MB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: PAS submission from Roche Products

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: PAS submission from Roche Products (PDF 567 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: PAS proposal from Roche Products (PDF 42 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: clarification

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: NICE request to the manufacturer for clarification on their submission - 1 (PDF 124 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: manufacturer's response to NICE's request for clarification - 1 (PDF 215 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: NICE request to the manufacturer for clarification on their submission - 2 (PDF 154 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: manufacturer's response to NICE's request for clarification - 2 (PDF 177 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: patient group, professional group and NHS organisation submission statements

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: British Association of Skin Cancer Nurse Specialists (PDF 105 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Nursing (PDF 45 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO) (PDF 82 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: expert written personal statements

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Chalk (PDF 300 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Fearfield (PDF 69 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Gore (PDF 328 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Lorigan (PDF 293 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Nuttall (PDF 95 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - final scope (PDF 50 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - draft scope for consultation (pre-referral) May 2011 (PDF 61 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - final matrix (PDF 58 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - provisional matrix (pre-referral) May 2011 (PDF 56 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix D - NICE's response to consultee and commentator comments on the draft scope and matrix (PDF 172 KB)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment (PDF 46 KB)